{"nctId":"NCT00092456","briefTitle":"Consistency Lots Vaccine Study (V260-009)","startDateStruct":{"date":"2003-05"},"conditions":["Rotavirus Infections"],"count":793,"armGroups":[{"label":"RotaTeq™ Lot 1","type":"EXPERIMENTAL","interventionNames":["Biological: rotavirus vaccine, live, oral, pentavalent"]},{"label":"RotaTeq™ Lot 2","type":"EXPERIMENTAL","interventionNames":["Biological: rotavirus vaccine, live, oral, pentavalent"]},{"label":"RotaTeq™ Lot 3","type":"EXPERIMENTAL","interventionNames":["Biological: rotavirus vaccine, live, oral, pentavalent"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"rotavirus vaccine, live, oral, pentavalent","otherNames":["V260","RotaTeq™"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants\n\nExclusion Criteria:\n\n* History of abdominal disorders from a birth defect, intussusception, or abdominal surgery\n* Known or suspected problems with the immune system\n* Fever at time of immunization\n* Prior administration of a rotavirus vaccine\n* History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]","description":"Antibody response to 3 manufactured lots of RotaTeq™ and placebo groups, based on the SNA PostDose 3 geometric mean titers (GMTs) (expressed in dilution units) against rotavirus serotypes G1, G2, G3, G4 and P1A\\[8\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167.9","spread":null},{"groupId":"OG001","value":"193.2","spread":null},{"groupId":"OG002","value":"171.0","spread":null},{"groupId":"OG003","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"22.6","spread":null},{"groupId":"OG002","value":"17.8","spread":null},{"groupId":"OG003","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":null},{"groupId":"OG001","value":"18.5","spread":null},{"groupId":"OG002","value":"14.6","spread":null},{"groupId":"OG003","value":"9.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0","spread":null},{"groupId":"OG001","value":"74.3","spread":null},{"groupId":"OG002","value":"65.7","spread":null},{"groupId":"OG003","value":"7.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"72.3","spread":null},{"groupId":"OG002","value":"65.6","spread":null},{"groupId":"OG003","value":"10.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Antibody Titer(s) (GMT) to Serum Anti-rotavirus Immunoglobulin A (IgA).","description":"Post Dose 3 serum samples were assayed for serum anti-rotavirus IgA","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292.7","spread":null},{"groupId":"OG001","value":"272.5","spread":null},{"groupId":"OG002","value":"266.2","spread":null},{"groupId":"OG003","value":"0.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With Clinical Adverse Experiences (CAEs)","description":"Subjects in this study were followed for all CAEs, including intussusception. A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"213","spread":null},{"groupId":"OG002","value":"212","spread":null},{"groupId":"OG003","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With Serious Clinical Adverse Experiences (SCAEs)","description":"Subjects were followed for all SCAEs. SCAEs are any CAEs occurring at any dose that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"220","spread":null},{"groupId":"OG002","value":"227","spread":null},{"groupId":"OG003","value":"108","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With Vaccine-Related Clinical AEs (CAEs)","description":"CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator, who is a qualified physician, as being related to the vaccine according to his/her best clinical judgment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"173","spread":null},{"groupId":"OG002","value":"165","spread":null},{"groupId":"OG003","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects With Serious Vaccine-Related Clinical AEs (CAEs)","description":"Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"224","spread":null},{"groupId":"OG002","value":"229","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects Discontinued Due to Clinical Adverse Experiences","description":"A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"224","spread":null},{"groupId":"OG002","value":"228","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects Discontinued Due to Vaccine-Related Clinical Adverse Experiences (CAEs)","description":"CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator who is a qualified physician as being related to the vaccine according to his/her best clinical judgment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"224","spread":null},{"groupId":"OG002","value":"229","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects Discontinued Due to Serious Clinical Adverse Experiences (SCAEs)","description":"SCAEs are any CAEs that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"224","spread":null},{"groupId":"OG002","value":"228","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Subjects Discontinued Due to Serious Vaccine-related Clinical Adverse Experiences (CAEs)","description":"Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"224","spread":null},{"groupId":"OG002","value":"229","spread":null},{"groupId":"OG003","value":"110","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":226},"commonTop":["Pyrexia","Diarrhoea","Vomiting","Upper respiratory tract infection","Otitis media"]}}}